Regal Investment Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History

Regal Investment Advisors’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$890K	Sell	2,691 -23	-0.8%	-$7.83K	0.05%	316
2025 Q4	$1.08M	Buy	2,714 +12	+0.4%	+$5.31K	0.06%	261
2025 Q3	$1.23M	Sell	2,702 -204	-7%	-$83.1K	0.08%	228
2025 Q2	$948K	Hold	2,906	–	–	0.07%	246
2025 Q1	$785K	Sell	2,906 -252	-8%	-$64.8K	0.06%	250
2024 Q4	$743K	Sell	3,158 -19	-0.6%	-$5K	0.06%	269
2024 Q3	$874K	Sell	3,177 -171	-5%	-$44.5K	0.06%	265
2024 Q2	$814K	Buy	3,348 +132	+4%	+$20.8K	0.05%	281
2024 Q1	$481K	Buy	3,216 +251	+8%	+$41.9K	0.03%	371
2023 Q4	$568K	Buy	2,965 +162	+6%	+$27.6K	0.04%	303
2023 Q3	$496K	Buy	2,803 +8	+0.3%	+$1.53K	0.04%	297
2023 Q2	$531K	Buy	2,795 +853	+44%	+$169K	0.04%	284
2023 Q1	$389K	Buy	+1,942	New	+$408K	0.03%	336

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Regal Investment Advisors's ALNY Position: Q1 2026 in Review

Regal Investment Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 0.85% in Q1 2026, selling an estimated $7.83K and leaving 2,691 shares worth $890K. The position accounts for 0.05% of the portfolio, ranked #316.

Regal Investment Advisors first reported a position in ALNY in Q1 2023 and has held it in 13 quarters since. The position peaked at $1.23M in Q3 2025. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Regal Investment Advisors held 2,691 shares of Alnylam Pharmaceuticals worth $890K as of Q1 2026.
Regal Investment Advisors sold 23 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $7.83K.
Alnylam Pharmaceuticals made up 0.05% of Regal Investment Advisors's portfolio in Q1 2026, its #316 holding.
Regal Investment Advisors first reported a position in Alnylam Pharmaceuticals in Q1 2023 and has held it in 13 quarters since.
Regal Investment Advisors's Alnylam Pharmaceuticals position peaked at $1.23M in Q3 2025.
786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Regal Investment Advisors's 13F filing for Q1 2026, filed 14 May 2026.